Hepatitis D Epidemiology Forecast

DelveInsight’s ‘Hepatitis D Virus (HDV) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted HDV epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030


Hepatitis D Virus (HDV) Understanding

Hepatitis D is caused by infection with the hepatitis D virus (HDV), also known as Delta Virus, and is considered to be the most severe form of viral hepatitis in humans due to more rapid progression toward liver-related death and hepatocellular carcinoma. HDV occurs only in individuals positive for the hepatitis B virus (HBV) surface antigen (HBsAg) as HDV is a defective RNA viroid that requires HBsAg for transmission. HDV shares common modes of transmission as HBV and can be acquired either as co-infection or super-infection to HBV. Simultaneous infection (i.e. co-infection) with HBV and HDV can lead to a mild-to-severe or even fulminant hepatitis, whereas the super-infection of HDV on chronic hepatitis B accelerates progression to a more severe disease in all ages and in 70‒90% of people.


The mode of transmission is commonly through contact with blood or other body fluids, including sexual contact with an infected partner, injection-drug use that involves sharing needles, syringes, or drug-preparation equipment and needle sticks or exposures to sharp instruments. Vertical transmission from mother to child is rare. Infection with HDV can worsen symptoms of HBV infection or hepatitis B-associated liver disease. It can cause symptoms to occur in people who previously did not have symptoms of HBV infection. The symptoms of HDV infection are similar to those experienced with HBV infection and can include yellowing of the skin and eyes (jaundice), gastrointestinal (GI) issues such as nausea, vomiting, and abdominal pain, tiredness, loss of appetite, dark-colored urine, joint pain, etc.


The severity of hepatitis D is influenced by the HDV genotype. Although infection with multiple genotypes may occur in patients at high risk of repeated exposure such as injecting drug users, a single genotype usually predominates with >10% of the viral load being represented by the minor strain. There are at least 8 genotypes (genetic variants) of HDV based on 14–38% sequence variation. These genotypes are associated with different long-term outcomes. Genotype 1 chronic HDV super-infection usually leads to a rapid progression to cirrhosis. Genotypes 2 and 4 cause a milder disease over a longer time course whereas genotype 3 is associated with advanced necroinflammatory.


Hepatitis D Virus (HDV) Diagnosis

The diagnosis of HDV is based on the medical history, a physical exam, and blood tests of the patients. HDV infection is diagnosed by high levels of Immunoglobulin G (IgG) and Immunoglobulin M (IgM) anti-HDV. As cases of hepatitis D are not clinically distinguishable from other types of acute viral hepatitis, diagnosis can be confirmed only by testing for the presence of antibodies against HDV and/or HDV RNA. The doctor may recommend tests to find out whether the patient has liver damage or how much liver damage or to rule out other causes of liver disease. These tests may include elastography, a special ultrasound that measures the stiffness of the liver, liver enzyme function tests, and a liver biopsy, wherein a doctor uses a needle to take a small piece of tissue from the liver.


Epidemiology Perspective by DelveInsight

The HDV epidemiology division provides insights about the historical and current HDV patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


Key Findings

  • In the year 2017, the total diagnosed prevalent case of HDV was 204,976 cases in the 7MM, and the US, in 2017, accounted for 112,673 cases (the highest number), which will probably rise during the study period, i.e., 2017–2030.
  • In the 7MM, the total gender-specific diagnosed prevalent cases of HDV were 129,470 for males and 75,506 for females in the year 2017.
  • In the 7MM, the Age-specific Diagnosed Prevalent Cases of HDV were 6,165, 52,598, 48,340, 51,462, 36,942, and 9,468 cases for the age group less than 18 years, 18–34 years, 35–44 years, 45–54 years, 55–64 years, and ≥65 years, in 2017.
  • In 2017, there were nearly 61,493 decompensated liver cases, and 143,483 Compensated Liver cases in the 7MM, which will probably rise during the study period, i.e., 2017–2030.

 

The disease epidemiology covered in the report provides historical as well as forecasted HDV epidemiology [segmented as Total Diagnosed Prevalent Cases of HDV, Gender-specific Diagnosed Prevalent Cases of HDV, Age-specific Diagnosed Prevalent Cases of HDV, Diagnosed Prevalent Cases of HDV by Impact on Liver, and Treated cases of HDV] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.


Country Wise- HDV Epidemiology

  • Estimates show that the highest cases of HDV in the 7MM were in the United States, followed by Japan, Germany, Italy, Spain, the United Kingdom, and France in 2017.
  • In the United States, the total diagnosed prevalent cases of HDV was 112,673 cases in the year 2017 which are expected to grow during the study period, i.e., 2017–2030.
  • In the year 2017, the total diagnosed prevalent cases of HDV were 64,845 cases in EU-5 which are expected to grow during the study period, i.e., 2017–2030.
  • In Japan, the total diagnosed prevalent cases of HDV was 27,458 cases in the year 2017 which are expected to grow during the study period, i.e., 2017–2030.


Scope of the Report

  • The HDV report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
  • The HDV Report and Model provide an overview of the risk factors and global trends of HDV in the seven major markets (7MM: The United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
  • The report provides insight about the historical and forecasted patient pool of HDV in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of HDV.
  • The report provides the segmentation of the HDV epidemiology by total diagnosed prevalent cases in the 7MM.
  • The report provides the segmentation of the HDV epidemiology by gender-specific diagnosed prevalent cases in the 7MM.
  • The report provides the segmentation of the HDV epidemiology by age-specific diagnosed prevalent cases in the 7MM.
  • The report provides the segmentation by diagnosed prevalent cases of HDV by the impact on the liver in the 7MM.
  • The report provides the segmentation of the HDV epidemiology by treated cases in the 7MM.


Report Highlights

  • 11-Year Forecast of HDV epidemiology
  • 7MM Coverage
  • Total Diagnosed Prevalent Cases of HDV
  • Gender-specific Diagnosed Prevalent Cases of HDV
  • Age-specific Diagnosed Prevalent Cases of HDV
  • Diagnosed Prevalent Cases of HDV by Impact on Liver
  • Treated Cases of HDV


KOL-Views

We interview KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population of HDV?
  • What are the key findings of the HDV epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017–2030)?
  • What would be the total number of patients of HDV across the 7MM during the study period (2017–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?
  • At what CAGR the patient population is expected to grow in the 7MM during the study period (2017–2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of HDV?


Reasons to buy

The HDV Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global HDV market
  • Quantify patient populations in the global HDV market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the gender that presents the best opportunities for HDV therapeutics in each of the markets covered
  • Understand the magnitude of the HDV population by its severity
  • The HDV epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
  • The HDV Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population


1. Key Insights

2. Executive Summary of the Hepatitis D Virus (HDV)

3. SWOT Analysis of Hepatitis D Virus (HDV)

4. Epidemiology Methodology

5. Hepatitis Delta Virus (HDV): Disease Background and Overview

5.1. Introduction

5.1.1. Signs and Symptoms of HDV

5.1.2. Risk Factors and Causes of HDV

5.1.3. Pathophysiology of HDV

5.1.4. Factors influencing HDV progression

5.1.5. Complications of HDV Infection

6. Diagnosis of Hepatitis D Infection

6.1. Physical exam

6.2. Blood Tests

6.2.1. Antibodies to HDV

6.2.2. HDV RNA

6.2.3. HD-Antigen

6.2.4. IgM Antibody to the Hepatitis B Core Antigen (IgM Anti-HBc)

6.2.5. HDV genotyping

6.3. Imaging Tests

6.4. Liver Biopsy

6.5. Differential diagnosis for HDV

7. Prevention of HDV

8. Epidemiology and Patient Population

8.1. Epidemiology Key Findings

8.2. Assumptions and Rationale: 7MM

9. Epidemiology Scenario: 7MM

9.1. Total Diagnosed Prevalent cases of HDV in the 7MM

9.2. Gender-specific Diagnosed Prevalent Cases of HDV in the 7MM

9.3. Age-specific Diagnosed Prevalent Cases of HDV in the 7MM

9.4. Diagnosed Prevalent Cases of HDV by Impact on Liver in the 7MM

9.5. Treated cases of HDV in the 7MM

10. The United States Epidemiology

10.1. Total Diagnosed Prevalent cases of HDV in the United States

10.2. Gender-specific Diagnosed Prevalent Cases of HDV in the United States

10.3. Age-specific Diagnosed Prevalent Cases of HDV in the United States

10.4. Diagnosed Prevalent Cases of HDV by Impact on Liver in the United States

10.5. Treated cases of HDV in the United States

11. EU-5 Epidemiology

11.1. Germany

11.1.1. Total Diagnosed Prevalent cases of HDV in Germany

11.1.2. Gender-specific Diagnosed Prevalent Cases of HDV in Germany

11.1.3. Age-specific Diagnosed Prevalent Cases of HDV in Germany

11.1.4. Diagnosed Prevalent Cases of HDV by Impact on Liver in Germany

11.1.5. Treated cases of HDV in Germany

11.2. France

11.2.1. Total Diagnosed Prevalent cases of HDV in France

11.2.2. Gender-specific Diagnosed Prevalent Cases of HDV in France

11.2.3. Age-specific Diagnosed Prevalent Cases of HDV in France

11.2.4. Diagnosed Prevalent Cases of HDV by Impact on Liver in France

11.2.5. Treated cases of HDV in France

11.3. Italy

11.3.1. Total Diagnosed Prevalent cases of HDV in Italy

11.3.2. Gender-specific Diagnosed Prevalent Cases of HDV in Italy

11.3.3. Age-specific Diagnosed Prevalent Cases of HDV in Italy

11.3.4. Diagnosed Prevalent Cases of HDV by Impact on Liver in Italy

11.3.5. Treated cases of HDV in Italy

11.4. Spain

11.4.1. Total Diagnosed Prevalent cases of HDV in Spain

11.4.2. Gender-specific Diagnosed Prevalent Cases of HDV in Spain

11.4.3. Age-specific Diagnosed Prevalent Cases of HDV in Spain

11.4.4. Diagnosed Prevalent Cases of HDV by Impact on Liver in Spain

11.4.5. Treated cases of HDV in Spain

11.5. The United Kingdom

11.5.1. Total Diagnosed Prevalent cases of HDV in the United Kingdom

11.5.2. Gender-specific Diagnosed Prevalent Cases of HDV in the United Kingdom

11.5.3. Age-specific Diagnosed Prevalent Cases of HDV in the United Kingdom

11.5.4. Diagnosed Prevalent Cases of HDV by Impact on Liver in the United Kingdom

11.5.5. Treated cases of HDV in the United Kingdom

12. Japan Epidemiology

12.1. Total Diagnosed Prevalent cases of HDV in Japan

12.2. Gender-specific Diagnosed Prevalent Cases of HDV in Japan

12.3. Age-specific Diagnosed Prevalent Cases of HDV in Japan

12.4. Diagnosed Prevalent Cases of HDV by Impact on Liver in Japan

12.5. Treated cases of HDV in Japan

13. Appendix

13.1. Bibliography

13.2. Report Methodology

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight

List of Table

 Table 1: Summary of the Hepatitis D Virus (HDV) Epidemiology (2017–2030)

Table 2: Summary of diagnostic tests for the evaluation of patients with HDV infection

Table 3: Total Diagnosed Prevalent cases of HDV in the 7MM (2017–2030)

Table 4: Gender-specific Diagnosed Prevalent Cases of HDV in the 7MM (2017–2030)

Table 5: Age-specific Prevalent Cases of HDV in the 7MM (2017–2030)

Table 6: Diagnosed Prevalent Cases of HDV by Impact on Liver in the 7MM (2017–2030)

Table 7: Total Treated cases of HDV in the 7MM (2017–2030)

Table 8: Total Diagnosed Prevalent cases of HDV in the United States (2017–2030)

Table 9: Gender-specific Diagnosed Prevalent Cases of HDV in the United States (2017–2030)

Table 10: Age-specific Prevalent Cases of HDV in the United States (2017–2030)

Table 11: Diagnosed Prevalent Cases of HDV by Impact on Liver in the United States (2017–2030)

Table 12:Total Treated cases of HDV in the United States (2017–2030)

Table 13: Total Diagnosed Prevalent cases of HDV in Germany (2017–2030)

Table 14: Gender-specific Diagnosed Prevalent Cases of HDV in Germany (2017–2030)

Table 15: Age-specific Prevalent Cases of HDV in Germany (2017–2030)

Table 16: Diagnosed Prevalent Cases of HDV by Impact on Liver in Germany (2017–2030)

Table 17: Total Treated cases of HDV in Germany (2017–2030)

Table 18: Total Diagnosed Prevalent cases of HDV in France (2017–2030)

Table 19: Gender-specific Diagnosed Prevalent Cases of HDV in France (2017–2030)

Table 20: Age-specific Prevalent Cases of HDV in France (2017–2030)

Table 21: Diagnosed Prevalent Cases of HDV by Impact on Liver in France (2017–2030)

Table 22: Total Treated cases of HDV in France (2017–2030)

Table 23: Total Diagnosed Prevalent cases of HDV in Italy (2017–2030)

Table 24: Gender-specific Diagnosed Prevalent Cases of HDV in Italy (2017–2030)

Table 25: Age-specific Prevalent Cases of HDV in Italy (2017–2030)

Table 26: Diagnosed Prevalent Cases of HDV by Impact on Liver in Italy (2017–2030)

Table 27: Total Treated cases of HDV in Italy (2017–2030)

Table 28: Total Diagnosed Prevalent cases of HDV in Spain (2017–2030)

Table 29: Gender-specific Diagnosed Prevalent Cases of HDV in Spain (2017–2030)

Table 30: Age-specific Prevalent Cases of HDV in Spain (2017–2030)

Table 31: Diagnosed Prevalent Cases of HDV by Impact on Liver in Spain (2017–2030)

Table 32: Total Treated cases of HDV in Spain (2017–2030)

Table 33: Total Diagnosed Prevalent cases of HDV in the United Kingdom (2017–2030)

Table 34: Gender-specific Diagnosed Prevalent Cases of HDV in the United Kingdom (2017–2030)

Table 35: Age-specific Prevalent Cases of HDV in the United Kingdom (2017–2030)

Table 36: Diagnosed Prevalent Cases of HDV by Impact on Liver in the United Kingdom (2017–2030)

Table 37: Total Treated cases of HDV in the United Kingdom (2017–2030)

Table 38: Total Diagnosed Prevalent cases of HDV in Japan (2017–2030)

Table 39: Gender-specific Diagnosed Prevalent Cases of HDV in Japan (2017–2030)

Table 40: Age-specific Prevalent Cases of HDV in Japan (2017–2030)

Table 41: Diagnosed Prevalent Cases of HDV by Impact on Liver in Japan (2017–2030)

Table 42: Total Treated cases of HDV in Japan (2017–2030)

List of Figures

 Figure 1: HDV SWOT Analysis

Figure 2: Epidemiology Methodology

Figure 3: Progression of HDV Infection

Figure 4: Signs and symptoms of HDV Infection

Figure 5: HBV-HDV Coinfection

Figure 6: HBV-HDV Superinfection

Figure 7: Causes of HDV

Figure 8: Virion structure of HDV

Figure 9: Virus Replication Cycle

Figure 10: Complications of HDV Infection

Figure 11: Diagnostic Algorithm of HDV

Figure 12: Blood Test

Figure 13: Percutaneous liver biopsy

Figure 14: Prevention of HDV

Figure 15: Total Diagnosed Prevalent cases of HDV in the 7MM (2017–2030)

Figure 16: Gender-specific Diagnosed Prevalent Cases of HDV in the 7MM (2017–2030)

Figure 17: Age-specific Diagnosed Prevalent Cases of HDV in the 7MM (2017–2030)

Figure 18: Diagnosed Prevalent Cases of HDV by Impact on Liver in the 7MM (2017–2030)

Figure 19: Treated cases of HDV in the 7MM (2017–2030)

Figure 20: Total Diagnosed Prevalent cases of HDV in the United States (2017–2030)

Figure 21: Gender-specific Diagnosed Prevalent Cases of HDV in the United States (2017–2030)

Figure 22: Age-specific Diagnosed Prevalent Cases of HDV in the United States (2017–2030)

Figure 23: Diagnosed Prevalent Cases of HDV by Impact on Liver in the United States (2017–2030)

Figure 24: Treated cases of HDV in the United States (2017–2030)

Figure 25: Total Diagnosed Prevalent cases of HDV in Germany (2017–2030)

Figure 26: Gender-specific Diagnosed Prevalent Cases of HDV in Germany (2017–2030)

Figure 27:Age-specific Diagnosed Prevalent Cases of HDV in Germany (2017–2030)

Figure 28: Diagnosed Prevalent Cases of HDV by Impact on Liver in Germany (2017–2030)

Figure 29: Treated cases of HDV in Germany (2017–2030)

Figure 30: Total Diagnosed Prevalent cases of HDV in France (2017–2030)

Figure 31: Gender-specific Diagnosed Prevalent Cases of HDV in France (2017–2030)

Figure 32:Age-specific Diagnosed Prevalent Cases of HDV in France (2017–2030)

Figure 33: Diagnosed Prevalent Cases of HDV by Impact on Liver in France (2017–2030)

Figure 34: Treated cases of HDV in France (2017–2030)

Figure 35: Total Diagnosed Prevalent cases of HDV in Italy (2017–2030)

Figure 36: Gender-specific Diagnosed Prevalent Cases of HDV in Italy (2017–2030)

Figure 37: Age-specific Diagnosed Prevalent Cases of HDV in Italy (2017–2030)

Figure 38: Diagnosed Prevalent Cases of HDV by Impact on Liver in Italy (2017–2030)

Figure 39: Treated cases of HDV in Italy (2017–2030)

Figure 40: Total Diagnosed Prevalent cases of HDV in Spain (2017–2030)

Figure 41: Gender-specific Diagnosed Prevalent Cases of HDV in Spain (2017–2030)

Figure 42: Age-specific Diagnosed Prevalent Cases of HDV in Spain (2017–2030)

Figure 43: Diagnosed Prevalent Cases of HDV by Impact on Liver in Spain (2017–2030)

Figure 44: Treated cases of HDV in Spain (2017–2030)

Figure 45: Total Diagnosed Prevalent cases of HDV in the United Kingdom (2017–2030)

Figure 46: Gender-specific Diagnosed Prevalent Cases of HDV in the United Kingdom (2017–2030)

Figure 47: Age-specific Diagnosed Prevalent Cases of HDV in the United Kingdom (2017–2030)

Figure 48: Diagnosed Prevalent Cases of HDV by Impact on Liver in the United Kingdom (2017–2030)

Figure 49: Treated cases of HDV in the United Kingdom (2017–2030)

Figure 50: Total Diagnosed Prevalent cases of HDV in Japan (2017–2030)

Figure 51: Gender-specific Diagnosed Prevalent Cases of HDV in Japan (2017–2030)

Figure 52: Age-specific Diagnosed Prevalent Cases of HDV in Japan (2017–2030)

Figure 53: Diagnosed Prevalent Cases of HDV by Impact on Liver in Japan (2017–2030)

Figure 54: Treated cases of HDV in Japan (2017–2030)

  • Tags:
  • Hepatitis D Epidemiology
  • Hepatitis D
  • Hepatitis D Pipeline
  • Hepatitis D Companies
  • Hepatitis D prevalent population
  • Hepatitis D incident population
  • Hepatitis D patients diagnosed
  • Hepatitis D treatment algorithm

Forward to Friend

Need A Quote